Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol

Executive Summary

With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients

You may also be interested in...



BMS Acquisition Strategy Heats Up With Kosan Buy

Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences

BMS Acquisition Strategy Heats Up With Kosan Buy

Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences

ODAC Split On Avastin Use In First-Line Metastatic Breast Cancer

FDA's Oncologic Drugs Advisory Committee creates a second obstacle to the approval of Genentech's Avastin in metastatic breast cancer by deciding that existing data do not establish a positive risk-benefit profile for a first-line indication. Genentech's primary obstacle is relying on a surrogate endpoint for full approval, in trying to use progression-free survival as a direct measure of clinical benefit

Related Content

UsernamePublicRestriction

Register

PS048914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel